Opiate Study – Press Release
National Access Cannabis & Phytosciences Consultants In The U.S. Launch Largest International Evidence-Based, Harm Reduction Approach To Prescription Opioid Use
National Access Cannabis in collaboration with Phytosciences Consultants in the U.S. will be establishing the largest Harm Reduction Study involving opioids and cannabis in North America. A two-year, evidence-based cohort study investigating the potential of prescribed pharmaceutical-grade cannabis as a substitute or in conjunction with opioids in the treatment of chronic pain and acute conditions. Patients will participate in periodic scientific based questionnaires administered by pharmacists. Canada and the U.S are at the center of an opioid epidemic. Deaths due to opioid overdose continue to rapidly rise in Canada making it second in highest users of opioids and third leading cause of accidental death in Ontario. To read full details on the harm reduction study visit www.opiatestudy.com.
The objective of the study is to assess the therapeutic satisfaction of patients using prescribed cannabis and to compare the subjective effects among the available formulations as compared to prescription opioid use. The results of this study may aid in further research, present information, options and next steps for developing an effective evidence-based policy for potential substitution of opioids.
In recent U.S. news, opioid overdose involving Fentanyl made headlines as the main factor in the unfortunate death of the musician Prince. While in Canada the numbers of opioid deaths and overdoses are increasing silently and rapidly to the extent that it has become a “national issue” according to a statement made by Donald MacPherson, executive director of the Canadian Drug Policy Coalition. Macpherson also stated the numbers of deaths are likely under-reported since Canada has a poor system of collecting statistics in this area. As well, it doesn’t include overdoses where death was avoided1. In 2007 an estimated 47,000 deaths a year were reported by the Health Officers Council of British Columbia. The Narcotics Control Board reports that Canadians use of opioids increased by 203% between 2000 and 20102.
The groundbreaking international Harm-Reduction Study that National Access Cannabis and Phytosciences Consultants will conduct is going to provide a basis to create clinical guidelines for healthcare practitioners. The vital missing information is in the clinical evidence healthcare practitioners need in order to advise patients on optimal dosages, formulations and routes of administration with respect to comorbidities, contraindications, adverse effects, drug-drug interactions and medical conditions.
About National Access Cannabis
National Access Cannabis operates in various cities across Canada and assists patients to improve their quality of life. Our cannabis consultants guide patients through the process of obtaining the required legal documents to possess medicinal cannabis. They also connect patients with a suitable legal, licensed producer approved by Health Canada. As well as educate patients on the various forms of consumption, plant varieties, cannabinoids, effects, etc.
National Access Cannabis has developed a secure, non-transferrable Medical Cannabis card and continues to work with law enforcement to achieve national recognition.
National Access Cannabis has an extensive physician network and connects patients with Health Canada approved licensed producers which test and regulate their cannabis. If you are interested in learning more about cannabis as an alternative therapy stop by head office located at 1111 Wellington Street in Ottawa West, call us at 613-729-8255 or contact us via web at NationalAccessCannabis.com.
About Phytosciences Consultants
Founded by President and CEO Dr. Pritesh Kumar, PhytoSciences was conceived to represent patients and to provide clinical trial solutions and quality control services to the medical cannabis industry. Phytoscience’s primary mission is to promote cannabinoid research, establish standards within the cannabis testing sector and serve as a global leader in ethical laboratory and testing practices.